In this prospective referring-physician–based survey, we investigated the definite clinical impact of ⁶⁸Ga-DOTATATE PET/CT on managing patients with neuroendocrine tumors (NETs). Methods: We prospectively studied 130 patients with ⁶⁸Ga-DOTATATE PET/CT referred for initial or subsequent management decisions (NCT02174679). Referring physicians completed one questionnaire before the scan (Q1) to indicate the treatment plan without PET/CT information, one immediately after review of the imaging report to denote intended management changes (Q2), and one 6 mo later (Q3) to verify whether intended changes were in fact implemented. To further validate the Q3 responses, a systematic electronic chart review was conducted. Results: All 3 questionnaires were completed by referring physicians for 96 of 130 patients (74%). ⁶⁸Ga-DOTATATE PET/CT resulted in intended management changes (Q2) in 48 of 96 patients (50%). These changes were finally implemented (Q3) in 36 of 48 patients (75%). Q3 responses were confirmed in all patients with an available electronic chart (36/96; 38%). Conclusion: This prospective study confirmed a significant impact of ⁶⁸Ga-DOTATATE PET/CT on the intended management of patients with NETs (50% of changes) and notably demonstrated a high implementation rate (75%) of these intended management changes.

在这项基于前瞻医师的调查中，我们研究了⁶⁸ Ga-DOTATATE PET / CT对管理神经内分泌肿瘤（NETs）患者的明确临床影响。方法：我们对130例⁶⁸ Ga-DOTATATE PET / CT患者进行了前瞻性或后续治疗决策（NCT02174679）的前瞻性研究。推荐医师在扫描前（Q1）完成一份问卷以指示没有PET / CT信息的治疗计划，在检查成像报告后立即完成一份问卷以表示预期的管理变更（Q2），并在6个月后完成一份问卷（Q3）以验证是否预期的更改实际上已经实施。为了进一步验证第三季度的响应，进行了系统的电子海图审查。结果：由130位患者中的96位（74％）的转诊医师完成了所有3份问卷。^68例Ga-DOTATATE PET / CT在96例患者中有48例（50％）导致了预期的管理改变（Q2）。这些变化最终在48例患者中的36例（75％）中得以实施（第3季度）。可用电子图表确认了所有患者的Q3应答（36/96； 38％）。结论：这项前瞻性研究证实了⁶⁸ Ga-DOTATATE PET / CT对NETs患者的预期治疗有显着影响（变化的50％），并且显着证明了这些预期治疗变化的实施率（75％）。